Search Result

Results for "

FAPi

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Biochemical Assay Reagents (1) Drug Derivative (2) Drug Intermediate (2) FAP (21) Prolyl Endopeptidase (PREP) (1) Radionuclide-Drug Conjugates (RDCs) (6)
By Research Areas:	Cancer (25)

Inhibitors & Agonists

Fluorescent Dye

Peptides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-147173

FAPI-74	FAP	Cancer
FAPI-74 is a PET (positron emission tomography) tracer targeting the fibroblast activation protein (FAP). FAPI-74 can be used for FAP-positive tumor research .

HY-128643

FAPI-4 Maximum Cited Publications 23 Publications Verification	FAP	Cancer
FAPI-4 is a potent fibroblast activation protein (FAP) inhibitor for the targeting FAP. FAPI-4 can be used in cancer research. ⁶⁸Ga-FAPI-4 PET/CT is a promising new diagnostic method for imaging various kinds of cancer, with good tumor-to-background contrast ratios .

HY-128642

FAPI-2	FAP	Cancer
FAPI-2 is a quinoline-based fibroblast activation protein (FAP)-targeting ligand that can be labeled as ⁶⁸Ga-FAPI-2 and used as a PET tracer for cancer diagnosis. FAPI-2 has advantages such as fast tracer kinetics, no need for fasting preparation, and being unaffected by blood glucose .

HY-137331

FAPI-46 1 Publications Verification	FAP	Cancer
FAPI-46 is a quinoline-based fibroblast activation protein (FAP)-targeted tracer. Use radioactivity FAPI-46 labeled with ⁶⁸Ga or ¹⁷⁷Lu can be used for tumor imaging in a variety of cancers and has higher tumor uptake rates and longer tumor accumulation .

HY-128642A

FAPI-2 TFA	FAP	Cancer
FAPI-2 TFA is a quinoline-based fibroblast activation protein (FAP)-targeting ligand that can be labeled as ⁶⁸Ga-FAPI-2 and used as a PET tracer for cancer diagnosis. FAPI-2 TFA has advantages such as fast tracer kinetics, no need for fasting preparation, and being unaffected by blood glucose .

HY-139401

FAPI-34 1 Publications Verification	FAP	Cancer
FAPI-34 is a fibroblast-activating protein (FAP) inhibitor with favorable pharmacokinetic and biochemical properties. (patent WO2019154886A1).

HY-164725

FAPI-mFS	Radionuclide-Drug Conjugates (RDCs) FAP	Cancer
FAPI-mFS is an irreversible fibroblast activation protein (FAP) inhibitor, that enhances the uptake and retention time in cancer cells through its covalent binding property for FAP. FAPI-mFS can be used for cancer imaging the therapy, when labeled with radioactive 68Ga or 177Lu . FAPI-mFS can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-47979

FAP-IN-2	FAP	Cancer
FAP-IN-2 is a derivative of ^99mTc-labeled isonitrile-containing fibroblast activation protein (FAPI) inhibitor. FAP-IN-2 can be used for tumor imaging. FAP-IN-2 has good stability, high uptake and good retention in the tumor site of mouse model .

HY-174421

FAPI-JNU	FAP	Cancer
FAPI-JNU is a molecule targeting fibroblast activation protein (FAP). FAPI-JNU specifically binds to FAP highly expressed in the tumor microenvironment, and uses radionuclides [ ⁶⁸Ga]Ga or [ ¹⁷⁷Lu]Lu to achieve tumor imaging diagnosis. [177Lu]Lu−FAPI−JNU can effectively target and inhibit tumor growth in tumor-bearing mice. FAPI-JNU is promising for research of FAP-positive tumors (such as various solid tumors) .

HY-172137

FAPI-FUSCC-07	FAP	Cancer
FAPI-FUSCC-07 is a targeted probe for fibroblast activation protein (FAP), exhibiting high affinity binding to FAP for applications in molecular imaging, tumor diagnosis, and radiotherapy .

HY-164364A

DOTAGA.(SA.FAPi)2 TFA	FAP	Cancer
DOTAGA.(SA.FAPi)2 TFA is a potent dimeric fibroblast-activation protein inhibitor (FAPi). DOTAGA.(SA.FAPi)2 TFA has the potential for cancer diagnosis research .

HY-136641

NOTA-FAPI	Radionuclide-Drug Conjugates (RDCs) FAP	Cancer
NOTA-FAPI is a fibroblast activation protein (FAP) inhibitor. NOTA-FAPI can be used as a probe for FAP-targeted tumour imaging. NOTA-FAPI has good tumour detection efficacy and excellent imaging quality .

HY-164316

*FT-FAPI-12_9*	FAP	Cancer
FT-FAPI-12_9 is a FAP-binding moiety, which can be used for synthesis of FAP-targeted radiotracer FAPI-46 (HY-137331) .

HY-164316A

*FT-FAPI-12_9 TFA*	FAP	Cancer
FT-FAPI-12_9 (TFA) is an FAP ligand that can be used for the synthesis of the FAP-targeted radiotracer FAPI-46 (HY-137331) .

HY-169868

*NOTA-FAPI-52*	Biochemical Assay Reagents	Cancer
NOTA-FAPI-52 is a tracer with potent tumor uptake. NOTA-FAPI-52 can be radiolabeled to enable PET imaging or other bioimaging techniques. NOTA-FAPI-52 can be used to study diseases in which fibroblast activation protein (FAP) is overexpressed .

HY-164364B

DOTAGA.(SA.FAPi)2 analogue TFA	FAP	Cancer
DOTAGA.(SA.FAPi)2 analogue TFA is a DOTAGA.(SA.FAPi)2 TFA (HY-164364A) analogue, in which the ligand and the chelator are identical to those of DOTAGA.(SA.FAPi)2 TFA. DOTAGA.(SA.FAPi)2 TFA is a potent dimeric fibroblast-activation protein inhibitor (FAPi) .

HY-D2363

DOTA.SA.FAPi TFA	FAP Radionuclide-Drug Conjugates (RDCs) Prolyl Endopeptidase (PREP)	Cancer
DOTA.SA.FAPi TFA inhibits fibroblast activation protein (FAP) with an IC₅₀ of 0.9 nM. DOTA.SA.FAPi TFA targets protease PREP with an IC₅₀ of 5.4 μM. DOTA.SA.FAPi TFA can be used a PET tracer, when labeled with ⁶⁸Ga, and used for research about cancer . DOTA.SA.FAPi (TFA) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-163079

AlF-PD-FAPI	FAP	Cancer
AlF-PD-FAPI has affinity for FAP , with the IC₅₀ of 0.13 nM, and shows a specific uptake, high internalized fraction, and low cellular efflux in vitro. AlF-PD-FAPI can be used as FAP-targeting tracer .

HY-170779

*DOTA-NI-FAPI-04*	FAP	Cancer
DOTA-NI-FAPI-04 is a FAP inhibitor (IC₅₀ = 7.44 nM). By integrating FAP targeting with hypoxia-sensitive groups (nitroimidazole), DOTA-NI-FAPI-04 significantly enhances tumor uptake and retention capabilities. DOTA-NI-FAPI-04 chelates metallic isotopes (such as ⁶⁸Ga and ¹⁷⁷Lu) through DOTA to produce radioactive probes ([ ⁶⁸Ga]Ga/DOTA-NI-FAPI-04 and [ ¹⁷⁷Lu]Lu/DOTA-NI-FAPI-04), which can be used for research in tumor diagnostics and therapeutic agents. DOTA-NI-FAPI-04 holds dual targeting potential in the fields of cancer imaging, tumor microenvironment analysis, and radionuclide therapy, particularly suitable for scenarios where the tumor stroma and hypoxic regions synergistically interact .

HY-159768A

*DOTAGA.Glu.(FAPi)2*	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTAGA.Glu.(FAPi)2 is a precursor for radiopharmaceutical labeling, which can be combined with radionuclides to create radionuclide drug conjugates (RDCs). RDCs have the capability to specifically target biomolecules and can be used in medical imaging .

HY-159767A

(S)-DOTAGA.(SA.FAPi)2	Radionuclide-Drug Conjugates (RDCs)	Cancer
(S)-DOTAGA.(SA.FAPi)2 is a precursor for radiopharmaceutical labeling, which can be combined with radionuclides to create radionuclide drug conjugates (RDCs). RDCs have the capability to specifically target biomolecules and can be used in medical imaging .

HY-159770A

*(S)-EB-FAPI-B2*	Radionuclide-Drug Conjugates (RDCs)	Cancer
(S)-EB-FAPI-B2 (Compound II-11) is a precursor for radiopharmaceutical labeling, which can be combined with radionuclides to create radionuclide drug conjugates (RDCs). RDCs have the capability to specifically target biomolecules and can be used in medical imaging or therapy .

HY-D2281

FAP Ligand 2	FAP	Cancer
FAP Ligand 2, a FAPI-46 derivative, is a specific fibroblast activation protein (FAP)-targeted tracer. FAP Ligand 2 exhibits good tumor uptake and acts as a promising molecular tracer for FAP tumor imaging .

HY-153552

NH2-UAMC1110	Drug Derivative FAP Drug Intermediate	Cancer
NH2-UAMC1110 is a UAMC1110 (HY-100684) derivative that can be used in the synthesis of FAPI-QS. FAPI-QS is a chelating agent that can be used to manufacture high tumor selectivity and high dose radiotracers for the diagnosis and treatment of tumors .

HY-153552A

NH2-UAMC1110 TFA	FAP Drug Intermediate Drug Derivative	Cancer
NH2-UAMC1110 TFA is a UAMC1110 (HY-100684) derivative that can be used in the synthesis of FAPI-QS. UAMC1110 is a fibroblast activation protein (FAP) inhibitor. FAPI-QS is a chelating agent that can be used to synthesize high tumor selectivity and high dose radiotracers for the diagnosis and treatment of tumors .

Cat. No.	Product Name	Type

HY-D2281

FAP Ligand 2	Dyes
FAP Ligand 2, a FAPI-46 derivative, is a specific fibroblast activation protein (FAP)-targeted tracer. FAP Ligand 2 exhibits good tumor uptake and acts as a promising molecular tracer for FAP tumor imaging .

Cat. No.	Product Name	Target	Research Area

HY-164725

FAPI-mFS	Radionuclide-Drug Conjugates (RDCs) FAP	Cancer
FAPI-mFS is an irreversible fibroblast activation protein (FAP) inhibitor, that enhances the uptake and retention time in cancer cells through its covalent binding property for FAP. FAPI-mFS can be used for cancer imaging the therapy, when labeled with radioactive 68Ga or 177Lu . FAPI-mFS can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-D2363

DOTA.SA.FAPi TFA	FAP Radionuclide-Drug Conjugates (RDCs) Prolyl Endopeptidase (PREP)	Cancer
DOTA.SA.FAPi TFA inhibits fibroblast activation protein (FAP) with an IC₅₀ of 0.9 nM. DOTA.SA.FAPi TFA targets protease PREP with an IC₅₀ of 5.4 μM. DOTA.SA.FAPi TFA can be used a PET tracer, when labeled with ⁶⁸Ga, and used for research about cancer . DOTA.SA.FAPi (TFA) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.